GENETIC DIAGNOSTIC KITS COMPOSED

Brand Owner (click to sort) Address Description
BAR CODE DIAGNOSTICS VYSIS, INC. 3100 Woodcreek Drive Downers Grove IL 605155400 genetic diagnostic kits composed of nucleic acid probes, detection reagents and antibodies for use in clinical medicine;genetic diagnostic kits composed of nucleic acid probes, detection reagents and antibodies for use in scientific research;
CEP VYSIS, INC. 3100 Woodcreek Drive Downers Grove IL 605155400 genetic diagnostic kits composed of DNA probes and related reagents for scientific research;
LSI Amoco Technology Company 305 East Shuman Boulevard Naperville IL 60540 genetic diagnostic kits composed of DNA probes and related reagents, used primarily for scientific research;
LSI ABBOTT MOLECULAR INC. 1300 E. Touhy Avenue Des Plaines IL 60018 genetic diagnostic kits composed of nucleic acid probes, detection reagents and antibodies for use in clinical medicine;genetic diagnostic kits composed of nucleic acid probes, detection reagents and antibodies for use in scientific research;
RSI Amoco Technology Company 305 East Shuman Boulevard Naperville IL 60540 genetic diagnostic kits composed of DNA probes and related reagents, used primarily for scientific research;
WCP ABBOTT MOLECULAR INC. 1300 E. Touhy Avenue Des Plaines IL 60018 genetic diagnostic kits composed of DNA probes and related reagents, for use in scientific research;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.